Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006146 · ClinicalTrials.gov registry record · Phase 2
Half-Dose Flu Vaccine Study in Healthy Adults
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 840
- Enrollment target
NCT00006146 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 840 participants.
The verdict
NCT00006146, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 840 participants
- Enrollment target
Study Summary
It appears likely that there will be a delay and possibly a reduction in the amount of influenza vaccine available for the 2000-2001 influenza season. One possible way of increasing the availability of influenza vaccine for this year is to use a half-dose in healthy adults. The objective of this study is to determine if the immune system responds to a half-dose the same way it responds to a whole dose. This study will use the currently approved inactivated influenza vaccine in healthy adults ages 18 to 49 years old. If the immune response to the half-dose is not significantly different than the immune response generated to the whole dose, this could be a strategy to extend the amount of vaccine that could be available in this age group.
Interventions
- BIOLOGICAL Approved influenza virus vaccine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2000-08 |
| Est. Completion | 2000-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006146
The ClinicalTrials.gov registry entry for NCT00006146 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Approved influenza virus vaccine. is the first listed.
NCT00006146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006146 about?
NCT00006146 is a clinical study titled "Half-Dose Flu Vaccine Study in Healthy Adults". It appears likely that there will be a delay and possibly a reduction in the amount of influenza vaccine available for the 2000-2001 influenza season. One possible way of increasing the availability of influenza vaccine for this year is to use a half-dose in healthy adults. The objective of this stu...
What is the current status of trial NCT00006146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 840 participants. The study started on 2000-08. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00006146?
The interventions under investigation include: Approved influenza virus vaccine. (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006146?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.